HUTCHMED (China) Limited HCM
15.08 USD -0.30 (-1.95%)
At closeNov 12, 2026, 4:00 AM EST
15.00 -0.08 -0.53%
Pre-market · Nov 12, 4:00 AM ET
14.81 Day range 15.20
9.77 52-week range 16.33
- YTD
- +13.13%
- 1 year
- -1.05%
News
globenewswire.com Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen…
prnewswire.com Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring – Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two…
benzinga.com Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent…
benzinga.com Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
benzinga.com HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned — ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…- benzinga.com HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…
benzinga.com Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application…
benzinga.com HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
benzinga.com Why Is HUTCHMED Stock Soaring Thursday? HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
benzinga.com Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
benzinga.com Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.- benzinga.com HUTCHMED Signs GSK Cancer Drug Deal Worth Up To $1.3B, Gets $110M Upfront HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a…
benzinga.com AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.
benzinga.com Reported Earlier, HUTCHMED Reports Late-Stage Results For New Lung Cancer Treatment Combo HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced…
benzinga.com AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu while halting a volrustomig study.
benzinga.com Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung…
benzinga.com HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percent decrease over earnings of $2.61 per share from the same period last year. The company reported…- benzinga.com Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14 Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.
- benzinga.com B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17 B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $20 to $17.
benzinga.com HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.- benzinga.com Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions — Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —— Fanregratinib holds promise as a new treatment option for…
benzinga.com Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo — Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment…- benzinga.com HUTCHMED And Innovent Biologics Announce That The Joint New Drug Application For The Combination Of Elunate And Tyvyt Has Been Granted Approval By The China National Medical Products Administration Companies granted approval by the China National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior…
- benzinga.com China Authority Accepts And Grants Priority Review To Hutchmed's Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia Patients Who Have Had An Insufficient Response To Prior Glucocorticoid Treatment HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") for sovleplenib for the treatment of adult patients with warm antibody autoimmune…
benzinga.com B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20 B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $21 to $20.- benzinga.com HUTCHMED Recalls Cancer Drug Tazverik in China After US Withdrawal Over Safety Risks HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc.…
benzinga.com Earnings Scheduled For March 5, 2026 - benzinga.com HUTCHMED (China) FY EPS $2.62 Beats $1.43 Estimate, Sales $548.512M Miss $591.425M Estimate HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.43 by 83.22 percent. This is a 1090.91 percent increase over earnings of…
benzinga.com An Overview of HUTCHMED (China)'s Earnings 
benzinga.com IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday - benzinga.com Earnings Scheduled For March 19, 2025
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
- benzinga.com AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session.
- benzinga.com Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
- benzinga.com Earnings Scheduled For July 31, 2023 Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
- benzinga.com Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719.
- benzinga.com Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
- benzinga.com Earnings Scheduled For February 28, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
- benzinga.com Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development…
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 413 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 404 stocks made new 52-week lows.
- benzinga.com Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 215 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.